Comparing normal skin from healthy donors to perilesional skin from the melanoma patients, we found a slight increase of pERK1/2 as well as an even more extensive increase in pERK1/2 expression in warts and tumor samples (Figure 8A), thereby confirming vemurafenib-dependent MEK-ERK activation also in skin keratinocytes in situ. This evidence concerns the gene MAP2K7 and neoplasm.